Table 2. Bioactivity types derived from high-throughput screenings against Plasmodium falciparum.

Sources are GSK TCAMS: GlaxoSmithKline Tres Cantos Antimalarial Screening [29]; Novartis-GNF: Novartis-GNF Malaria Box dataset [50]; and SJCRH: Saint Jude Children's Research Hospital [30].

Bioactivity type / Assay	Compounds	Bioactivities	Positive	Cutoff	Source
% growth inhibition Pf 3D7 at 2 μM	13,469	13,519	13,484	> = 80%	GSK TCAMS
% growth inhibition Pf Dd2 at 2 μM	13,469	13,519	5,061	> = 80%	GSK TCAMS
EC50 Pf 3D7	5,387	5,497	4,523	2 μM	Novartis-GNF
EC50 Pf W2	5,375	5,485	4,804	2 μM	Novartis-GNF
EC50 Pf 3D7	172	172	152	2 μM	SJCRH
EC50 Pf V1/S	172	172	141	2 μM	SJCRH
EC50 Pf 3D7, SYBR green	1,524	1,536	496	2 μM	SJCRH
% growth inhibition at 7 μM	1,524	3,072	2,475	> = 80%	SJCRH
EC50 PfK1, by SYBR green	1,524	1,536	488	2 μM	SJCRH
EC50 PfD10_yDHOD	172	172	136	2 μM	SJCRH
EC50 PfDd2	172	172	158	2 μM	SJCRH
EC50 PfK1	172	172	153	2 μM	SJCRH
EC50 PfSB-A6	172	172	129	2 μM	SJCRH
EC50 PfW2	172	172	116	2 μM	SJCRH